Nephrology

Living donation: What's truly behind rapid APOL1 kidney decline?

Individuals with two APOL1 risk alleles experience a greater decline in kidney function after living donation, raising concerns for donor selection.

C3G: Pegcetacoplan or iptacopan? Why indirect data complicates your choice

Indirect comparisons suggest pegcetacoplan may offer superior efficacy in C3 glomerulopathy, but head-to-head trials are absent.

IgAV-N in children: High risk, low evidence. A path for better trials

IgA vasculitis nephritis in children progresses to kidney failure, but clinical studies are few. An international workshop identified barriers to high-quality evidence.

Why children with IgA vasculitis nephritis still lack targeted therapies

New KDIGO guidelines highlight a persistent gap in clinical trial data for children with IgA vasculitis nephritis, leaving them without specific treatment recommendations.

IgA Nephritis: Known threat, unknown plan for older transplants

Current research on IgA nephritis post-transplant largely excludes older patients, leaving a significant gap in evidence for managing this complex population.

Why nephrology inpatients are sicker, more complex, and harder to manage

Nephrology inpatients present with increasing comorbidity burden and acuity, driven by an aging population and advanced chronic kidney disease.

Is Fabhalta the long-term IgAN solution we've needed?

Fabhalta (iptacopan) received full FDA approval for IgA nephropathy, converting its accelerated approval based on proteinuria reduction.

AI-Triggered Nephrology Consult Fails to Prevent AKI in Trial

An AI-driven alert system for acute kidney injury risk did not reduce AKI incidence or severity when triggering nephrology consults in hospitalised patients.

Waist Size, Muscle Mass Predict CKD Prognosis, Mortality Risk

Abdominal obesity and sarcopenia are independent predictors of adverse outcomes in chronic kidney disease (CKD), influencing mortality and disease progression.